Press Releases Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Real-time Estimate Cboe BZX Other stock markets 10:56:21 09/05/2024 pm IST			5-day change	1st Jan Change
6.75 ^USD	-16.87%		-18.92%	-41.17%

03:55pm	Ironwood Pharmaceuticals' Shares Fall After Q1 Swings to a Non-GAAP Loss, Revenue Declines; 2024 Revenue Guidance Cut	MT
02:30pm	Transcript : Ironwood Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ironwood Pharmaceuticals : 1Q 2024 Investor Update	05:32pm	PU
Ironwood: Q1 Earnings Snapshot	04:42pm	AQ
Ironwood Pharmaceuticals Reports First Quarter 2024 Results	04:31pm	BU
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference	07/05	BU
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024	01/05	BU
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call	26/04	BU
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	28/03	BU
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure	01/03	AQ
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)	29/02	BU
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science and Practice Conference	26/02	AQ
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference	23/02	BU
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results, Achieves 2023 Financial Guidance	16/02	AQ
Ironwood: Q4 Earnings Snapshot	15/02	AQ
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance	15/02	BU
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call	02/02	BU
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation	09/01	BU
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance	08/01	BU
Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference	04/01	BU
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio	13/12	BU
Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference	22/11	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Press Releases

Filters